Is Your Drug Testing Business Ready to Sell?

Buyers will discount top-line revenue that includes pass-through lab and MRO costs with little or no margin. Rebuild your P&L to clearly show collection fees, MRO service fees, and consortium management revenue as distinct line items, with lab pass-throughs presented as a cost of goods rather than gross revenue where appropriate. This is the single most common valuation disconnect in drug testing transactions.

Accrual-basis financials prepared or reviewed by a CPA are the baseline expectation for any deal above $1M in value. If your books are cash-basis or tax-return-only, engage a CPA now to recast three years of statements. Buyers using SBA 7(a) financing will require this documentation from their lender before issuing a term sheet.

Add back owner compensation above market replacement cost, personal vehicle expenses, one-time equipment purchases, and non-recurring compliance remediation costs. Document each add-back with supporting invoices or payroll records. In drug testing businesses, owner-paid certification renewal fees and personal cell phones used for client account management are common legitimate add-backs.

Build a client-by-client revenue table showing each employer account's trailing twelve-month testing volume, revenue, and percentage of total. Flag any client exceeding 15–20% of total revenue as a concentration risk that buyers will price into their offer or address with earnout provisions. Diversification across transportation, construction, healthcare, and government segments is a meaningful value driver.

Buyers will request copies of every collector's DOT qualification training certificate. Any lapsed or expiring certification becomes a due diligence flag and could trigger a price reduction or closing condition. Schedule refresher training now for any collector within 12 months of expiration. Confirm your designated employer representative (DER) designations are documented for each DOT-regulated client.

Document every DOT compliance inspection, SAMHSA-related audit, or state occupational health review conducted in the past five years, along with your responses and resolutions. If your business has received citations or consent orders, prepare a written explanation and corrective action narrative. Buyers will find this in due diligence regardless — presenting it proactively demonstrates integrity and reduces uncertainty.

Buyers need assurance that your laboratory testing relationships — which underpin your service delivery — will transfer at close. Pull your current lab agreements and confirm they include assignment or change-of-control provisions, or that the lab will sign a consent to assignment. If agreements are informal or verbal, formalize them now with written contracts specifying pricing, turnaround times, and termination notice periods.

Drug testing businesses handle protected health information subject to HIPAA. Buyers will ask for your privacy policy, business associate agreements with labs and MRO providers, and evidence of staff HIPAA training. If your BAAs are missing or outdated, complete them now. A HIPAA compliance gap is a red flag for both strategic acquirers and their legal counsel.

Many states require separate collection site registration, occupational health clinic permits, or drug-free workplace program administrator licenses. Map every jurisdiction where you operate and confirm license status, renewal dates, and transferability. Some licenses require new owner re-application which can delay close by 30–90 days if not anticipated.

The most common challenge in drug testing transactions is that employer relationships are governed by purchase orders or informal arrangements rather than signed contracts. Even a 12-month agreement with auto-renewal and 30-day termination notice converts a perceived at-risk relationship into documented recurring revenue. Prioritize converting your top 10 accounts by revenue before going to market.

If you outsource Medical Review Officer services, pull those agreements and confirm pricing, volume commitments, and assignment terms. If you perform MRO in-house as a certified MRO physician, document that credential and assess whether it's transferable to a buyer or whether an MRO services contract with a third party needs to be established before close to protect revenue continuity.

Document every step in your collection workflow: specimen receipt, chain-of-custody form completion, specimen labeling, shipping protocols, result reporting, and MRO escalation procedures. This manual is both a buyer confidence signal and a practical transition tool. Buyers backed by PE platforms will require documented SOPs as a condition of their operational integration.

Consortium management is one of the highest-margin, most recurring revenue streams in drug testing. Create a schedule of every employer enrolled in your DOT random testing consortium, their annual management fee, and their random selection history. This schedule is a key exhibit in your confidential information memorandum and is often the asset buyers value most.

Buyers will evaluate whether your collection management software, laboratory information management system integrations, and result delivery platform are scalable and compatible with their own systems. Document your current technology stack, any integrations with employer HR or payroll platforms, and identify gaps relative to competitors offering real-time digital reporting. Address critical gaps before going to market.

If your service model includes a mobile collection fleet or agreements with third-party collection sites, document those arrangements formally. Fleet vehicles should be valued and included in the asset schedule. Third-party site agreements should specify exclusivity, territory, and termination notice to protect your network post-close.

If employer clients call you personally for test results, compliance questions, or account issues, those relationships are at risk at close. Identify your top 10 accounts by revenue and systematically introduce a key employee as the primary contact over 6–12 months before marketing the business. Document each transition in your CRM. This is the highest-impact operational change you can make to improve your valuation.

Buyers — especially those using SBA financing — will want to know who runs the business if the owner is not present. Identify and, if necessary, promote or hire an operations manager who can manage collector scheduling, client communication, and regulatory compliance independently. A retention bonus or equity carve tied to deal close can help lock this person in through transition.

Drug testing businesses are valued differently than general service businesses due to pass-through revenue complexity, regulatory licensing, and the recurring revenue dynamics of consortium management. Work with an advisor who has sold occupational health or compliance services businesses and can accurately frame your EBITDA, client retention metrics, and regulatory standing for qualified buyers.

Build a cohort retention table showing how many employer accounts were active each year for the past three years, how many renewed, and how many churned. Calculate your annual gross and net revenue retention rates. A drug testing business with 90%+ annual retention across its employer base is a compelling acquisition story — and the data to prove it should be ready before your first buyer conversation.

Drug testing businesses are typically sold as asset purchases with consideration allocated across goodwill, client lists, equipment, and non-compete agreements — each with different tax treatment. Understanding whether an S-corp election, installment sale treatment on a seller note, or equity rollover structure benefits your situation before negotiations begin can meaningfully increase your net proceeds without changing the headline purchase price.